SPAC22E12.01 Antibody

What is SPAC22E12.01 and what organism does it originate from?

SPAC22E12.01 is a gene encoding an uncharacterized transporter protein C22E12.01 in Schizosaccharomyces pombe (fission yeast). It is also known by the alternative identifier SPAC890.09 and is predicted to function as a triose phosphate transporter based on sequence analysis . Understanding the biological context of this protein is essential for designing appropriate experimental controls and interpreting results when working with antibodies targeting this protein.

What types of SPAC22E12.01 antibodies are currently available for research?

Currently, rabbit polyclonal antibodies against Schizosaccharomyces pombe SPAC22E12.01 are available for research applications. These antibodies are typically generated using antigen-affinity purification methods and are of IgG isotype . Additionally, researchers can access recombinant SPAC22E12.01 protein products that can be utilized for antibody production, validation studies, or as controls in experimental workflows involving the detection of this transporter protein .

What are the validated applications for SPAC22E12.01 antibodies?

SPAC22E12.01 antibodies have been validated for use in Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) applications . These applications enable researchers to detect and quantify the presence of the SPAC22E12.01 protein in experimental samples. When selecting an antibody for your research, it is crucial to verify that it has been validated for your specific application to ensure reliable and reproducible results, as inadequate antibody characterization has been identified as a significant source of irreproducibility in biomedical research .

How should I design proper control experiments when using SPAC22E12.01 antibodies?

When designing control experiments for SPAC22E12.01 antibody studies, implement the following strategy:

• Positive controls: Include samples known to express SPAC22E12.01 protein, such as wild-type S. pombe lysates.

• Negative controls: Use samples from SPAC22E12.01 knockout strains or species known not to express homologous proteins.

• Antibody controls: Include secondary antibody-only controls to assess non-specific binding.

• Blocking peptide controls: Pre-incubate the antibody with purified recombinant SPAC22E12.01 protein to confirm specificity.

• Cross-reactivity assessment: Test against related proteins or in non-target species if working in heterologous systems.

This comprehensive approach helps prevent misleading interpretations from inadequately characterized antibodies, which has become a significant concern in biomedical research reproducibility .

What is the recommended protocol for using SPAC22E12.01 antibodies in Western blotting?

For optimal Western blot results with SPAC22E12.01 antibodies:

• Sample preparation: Extract proteins from S. pombe using a detergent-based lysis buffer containing protease inhibitors.

• Protein loading: Load 20-50 μg of total protein per lane.

• Electrophoresis: Separate proteins using 10-12% SDS-PAGE.

• Transfer: Use PVDF membrane for optimal protein binding.

• Blocking: Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute SPAC22E12.01 antibody (typically 1:500-1:2000, but verify manufacturer's recommendations) in blocking buffer and incubate overnight at 4°C.

• Washing: Wash 3-5 times with TBST, 5 minutes each.

• Secondary antibody: Apply appropriate HRP-conjugated or fluorescently labeled secondary antibody.

• Detection: Develop using chemiluminescence or fluorescence imaging systems.

• Analysis: Quantify band intensity using appropriate software.

Include both positive and negative controls to ensure specificity and validate results .

How can I optimize ELISA protocols for detecting SPAC22E12.01 protein?

To optimize ELISA detection of SPAC22E12.01:

• Plate coating: Coat high-binding ELISA plates with capture antibody (1-10 μg/ml) in carbonate buffer (pH 9.6) overnight at 4°C.

• Blocking: Block with 2-5% BSA in PBS for 1-2 hours at room temperature.

• Sample preparation: Prepare serial dilutions of samples and recombinant SPAC22E12.01 standards.

• Primary incubation: Add samples and standards to wells, incubate for 2 hours at room temperature or overnight at 4°C.

• Detection antibody: Apply biotinylated or enzyme-conjugated SPAC22E12.01 antibody.

• Signal development: Use streptavidin-HRP followed by appropriate substrate (TMB, ABTS) or direct enzymatic detection.

• Optimization parameters:

  • Evaluate multiple antibody pairs for sandwich ELISA

  • Test different blocking reagents (BSA, milk, commercial blockers)

  • Optimize antibody concentrations using checkerboard titration

  • Compare different detection systems for optimal signal-to-noise ratio

This methodical approach ensures specific and sensitive detection, addressing the critical need for proper antibody characterization in research applications .

How can I validate SPAC22E12.01 antibody specificity in immunofluorescence microscopy experiments?

For rigorous validation of SPAC22E12.01 antibodies in immunofluorescence applications:

• Genetic validation: Compare staining patterns between wild-type S. pombe and SPAC22E12.01 deletion mutants.

• Tagged protein controls: Co-localize antibody signal with fluorescently tagged SPAC22E12.01 protein expressed at endogenous levels.

• Peptide competition: Pre-incubate antibody with excess recombinant SPAC22E12.01 protein before staining; this should abolish specific signal.

• siRNA knockdown: If working in a heterologous system, compare antibody staining in cells with and without siRNA-mediated knockdown.

• Subcellular fractionation validation: Correlate microscopy localization with biochemical fractionation results.

• Specificity controls:

  • Test pre-immune serum (for polyclonal antibodies)

  • Include secondary antibody-only controls

  • Test cross-reactivity with related transporter proteins

Document all validation steps methodically, as proper antibody validation is critical for research reproducibility . If using rhodamine-conjugated antibodies, optimize imaging parameters using appropriate excitation (530 nm) and emission (580 nm) filters .

What approaches can be used to study the molecular function of SPAC22E12.01 using antibodies?

To investigate SPAC22E12.01 molecular function using antibody-based approaches:

• Co-immunoprecipitation (Co-IP):

  • Use SPAC22E12.01 antibodies to pull down the protein and identify interaction partners by mass spectrometry

  • Verify interactions through reciprocal Co-IP experiments

  • Map interaction domains using truncated protein constructs

• Chromatin Immunoprecipitation (ChIP):

  • If SPAC22E12.01 has potential transcriptional roles, use ChIP to identify DNA binding sites

  • Combine with sequencing (ChIP-seq) for genome-wide binding profiles

• Proximity-dependent labeling:

  • Combine antibody-based detection with BioID or APEX2 proximity labeling

  • Map the protein's immediate molecular neighborhood

• Structure-function analysis:

  • Use antibodies recognizing specific domains or post-translational modifications

  • Correlate functional changes with structural alterations

• Transport assays:

  • Since SPAC22E12.01 is predicted to be a triose phosphate transporter, use antibodies to characterize its localization during transport assays

  • Develop blocking antibodies that might inhibit transport function

How can SPAC22E12.01 antibodies be used in combination with other tools for comprehensive protein characterization?

For comprehensive characterization of SPAC22E12.01:

• Multi-omics integration:

  • Combine immunoprecipitation with mass spectrometry (IP-MS) to identify post-translational modifications

  • Correlate protein expression (detected by antibodies) with transcriptomic data

  • Map protein-protein interactions using antibody-based proximity ligation assays

• Structural biology approaches:

  • Use antibodies to facilitate protein crystallization

  • Employ antibody fragments for cryo-EM structural studies

  • Develop conformational-specific antibodies to capture different protein states

• Functional genomics integration:

  • Combine CRISPR-based genetic screens with antibody-based protein detection

  • Correlate phenotypic changes with protein expression/modification patterns

  • Use antibodies to validate genetic screen hits

• Temporal analysis:

  • Implement time-course studies with antibody detection at multiple timepoints

  • Use antibodies against modification-specific epitopes to track signaling dynamics

This integrative approach enhances research reproducibility by validating findings through multiple methodologies, addressing concerns about antibody specificity that have contributed to reproducibility issues in biomedical research .

What are the common pitfalls when using SPAC22E12.01 antibodies and how can they be addressed?

When working with SPAC22E12.01 antibodies, researchers commonly encounter these challenges:

• Non-specific binding:

  • Problem: Multiple bands in Western blots or diffuse staining in immunofluorescence

  • Solution: Optimize blocking conditions (try different blockers like BSA, milk, or commercial alternatives); increase washing stringency; validate with SPAC22E12.01 knockout controls

• Weak or absent signal:

  • Problem: Inability to detect target protein

  • Solution: Confirm protein expression levels; optimize antibody concentration; try different epitope exposure methods (heat-induced, citrate, or EDTA-based); consider protein enrichment before detection

• Batch-to-batch variability:

  • Problem: Inconsistent results between antibody lots

  • Solution: Characterize each new lot against reference samples; maintain detailed records of antibody performance; consider monoclonal alternatives if available

• Cross-reactivity with related proteins:

  • Problem: Signal detection in systems without SPAC22E12.01

  • Solution: Perform specificity tests using recombinant proteins; validate with genetic knockout models; use peptide competition assays

These approaches address the well-documented challenges of antibody reproducibility in research, emphasizing proper characterization to ensure reliable results .

How can I quantitatively assess the specificity and sensitivity of SPAC22E12.01 antibodies?

To rigorously assess SPAC22E12.01 antibody performance:

• Specificity assessment:

  • Western blot analysis against recombinant SPAC22E12.01 and related proteins

  • Immunoprecipitation followed by mass spectrometry to identify all captured proteins

  • Testing against samples from knockout organisms

  • Quantification metrics: Calculate specificity ratio (target signal/non-target signal)

• Sensitivity analysis:

  • Generate standard curves using purified SPAC22E12.01 protein at known concentrations

  • Determine limit of detection (LOD) and limit of quantification (LOQ)

  • Calculate signal-to-noise ratios at different protein concentrations

  • Sensitivity metric: LOD = mean(blank) + 3×SD(blank)

• Reproducibility assessment:

  • Perform replicate experiments under identical conditions

  • Calculate coefficient of variation (%CV) across replicates

  • Evaluate inter-day and inter-operator variability

  • Acceptable standard: %CV < 15% for quantitative applications

• Validation table (to document for each application):

This systematic approach addresses the antibody characterization crisis highlighted in literature, where inadequate validation has led to irreproducible results .

What are the best practices for storing and handling SPAC22E12.01 antibodies to maintain their activity?

For optimal maintenance of SPAC22E12.01 antibody activity:

• Storage conditions:

  • Store antibody aliquots at -20°C for long-term storage

  • Avoid repeated freeze-thaw cycles (limit to <5)

  • For working solutions, store at 4°C with appropriate preservatives

  • Lyophilized antibodies should be reconstituted according to manufacturer instructions, typically using deionized water and allowing 30 minutes on ice before use

• Handling protocol:

  • Centrifuge briefly before opening to collect contents at the bottom of the tube

  • Use sterile techniques when handling antibody solutions

  • Add carrier proteins (0.1-1% BSA) to dilute antibody solutions to prevent adsorption to tubes

  • Use non-stick tubes for very dilute antibody solutions

• Stability monitoring:

  • Include positive control samples in each experiment to monitor antibody performance over time

  • Document lot numbers, receipt dates, and performance metrics for each antibody

  • Consider using stabilizing agents like glycerol (final concentration 30-50%) for frequently used antibodies

• Reconstitution best practices:

  • Follow manufacturer's buffer recommendations precisely

  • For rhodamine-conjugated antibodies, protect from light during handling and storage

  • Maintain appropriate preservative concentrations (e.g., sodium azide at 0.02-0.05%)

Adhering to these practices helps ensure reproducible results and addresses concerns about antibody reliability in research, which has been identified as a significant challenge in biomedical research .

How can I develop and validate custom SPAC22E12.01 antibodies for specific research applications?

For developing custom SPAC22E12.01 antibodies:

• Antigen design strategy:

  • Identify unique epitopes using bioinformatic analysis to avoid cross-reactivity

  • Consider multiple approaches:

    • Recombinant protein expression (full-length or domains)

    • Synthetic peptides conjugated to carrier proteins (KLH/BSA)

    • DNA immunization encoding SPAC22E12.01

• Production options:

  • Monoclonal antibody development via hybridoma technology:

    • Immunize animals (typically mice or rats)

    • Fusion of B cells with myeloma cells

    • Screening and selection of positive hybridoma clones

  • Polyclonal antibody generation:

    • Immunize rabbits or other suitable species

    • Collect and purify antibodies from serum

  • Recombinant antibody production:

    • Phage display selection

    • Expression in appropriate systems (E. coli, mammalian cells)

• Comprehensive validation workflow:

  • Western blot against recombinant protein and native samples

  • Immunoprecipitation followed by mass spectrometry

  • Testing against knockout/knockdown samples

  • Cross-reactivity assessment against related proteins

  • Application-specific validation (IF, IHC, ChIP, etc.)

• Documentation requirements:

  • Complete epitope information

  • Full validation dataset

  • Production method details

  • Species reactivity profile

  • Batch-to-batch consistency data

This systematic approach addresses the antibody reproducibility crisis by ensuring proper characterization from development through application .

How can SPAC22E12.01 antibodies be used to study protein-protein interactions and complex formation?

For investigating SPAC22E12.01 protein interactions:

• Co-immunoprecipitation (Co-IP) methodology:

  • Cross-linking optimization: Test different concentrations of formaldehyde or DSS

  • Lysis buffer selection: Compare detergent types (NP-40, Triton X-100, CHAPS) and strengths

  • IP protocol:

    • Pre-clear lysates with protein A/G beads

    • Incubate with SPAC22E12.01 antibody

    • Capture with protein A/G beads

    • Wash stringently to remove non-specific interactions

    • Elute and analyze by Western blot or mass spectrometry

• Proximity ligation assay (PLA):

  • Combine SPAC22E12.01 antibody with antibodies against suspected interaction partners

  • Use species-specific secondary antibodies conjugated with oligonucleotides

  • Positive signal occurs only when proteins are within 40nm

  • Quantify interaction points microscopically

• FRET/BRET approaches with antibody validation:

  • Use antibodies to validate energy transfer results

  • Confirm protein expression levels and localization

• Native gel electrophoresis:

  • Use non-denaturing conditions to preserve protein complexes

  • Detect with SPAC22E12.01 antibodies

  • Compare migration patterns under different conditions

• Data analysis and representation:

This methodical approach helps ensure reproducible investigation of protein-protein interactions, addressing concerns about antibody-based research reliability .

What strategies can be employed to multiplex SPAC22E12.01 antibody detection with other cellular markers?

For multiplexed detection involving SPAC22E12.01:

• Fluorescence microscopy multiplexing:

  • Spectral separation approach:

    • Select antibodies with distinct fluorophores (e.g., SPAC22E12.01 with rhodamine, λEx/Em: 530/580nm)

    • Combine with far-red or blue fluorophores for maximum separation

    • Use linear unmixing algorithms for closely spaced emission spectra

  • Sequential detection:

    • Apply, image, and strip/quench antibodies sequentially

    • Document registration markers for image alignment

• Flow cytometry multiplexing:

  • Panel design considerations:

    • Balance fluorophore brightness with target abundance

    • Account for spectral overlap and compensation requirements

    • Include FMO (Fluorescence Minus One) controls

  • Optimization strategy:

    • Titrate each antibody individually

    • Test in combination to identify interference

    • Validate with appropriate controls

• Multiplex Western blotting:

  • Size-based multiplexing:

    • Use antibodies from the same species if targets differ sufficiently in size

    • Employ fluorescent secondary antibodies with distinct spectra

  • Advanced approaches:

    • Sequential probing/stripping

    • Multiplex fluorescent detection systems combining SPAC22E12.01 detection with housekeeping proteins

• Mass cytometry (CyTOF):

  • Label SPAC22E12.01 antibodies with rare earth metals

  • Combine with antibodies against other cellular markers

  • Analyze using mass spectrometry for highly multiplexed detection

This systematic approach to multiplexing facilitates comprehensive cellular analysis while maintaining detection specificity, which is critical given concerns about antibody specificity in research applications .

What emerging technologies might enhance SPAC22E12.01 antibody applications in research?

Several cutting-edge technologies are poised to revolutionize SPAC22E12.01 antibody applications:

• Single-cell antibody-based proteomics:

  • Integration with single-cell RNA-seq for correlative analysis

  • Microfluidic antibody-based detection systems allowing high-throughput single-cell protein quantification

  • Spatial proteomics approaches to map SPAC22E12.01 localization in subcellular compartments

• Advanced imaging technologies:

  • Super-resolution microscopy (STED, PALM, STORM) combined with SPAC22E12.01 antibodies for nanoscale localization

  • Expansion microscopy to physically magnify samples for enhanced resolution

  • Light-sheet microscopy for rapid 3D imaging of large specimens

• Antibody engineering innovations:

  • Nanobodies or single-domain antibodies against SPAC22E12.01 for improved penetration

  • Bispecific antibodies for co-detection of SPAC22E12.01 and interaction partners

  • Intrabodies designed for live-cell applications

• AI-enhanced antibody validation:

  • Machine learning algorithms to predict antibody specificity and performance

  • Automated image analysis pipelines for standardized antibody validation

  • Computational tools to design optimally specific antibodies

These emerging technologies address the ongoing challenges in antibody research reproducibility by providing more precise, quantitative, and standardized approaches to protein detection and characterization .

How can researchers contribute to improving the reproducibility of studies involving SPAC22E12.01 antibodies?

Researchers can enhance reproducibility of SPAC22E12.01 antibody studies through:

• Comprehensive validation and reporting:

  • Implement the 5 pillars of antibody validation:

    • Genetic strategies (knockout/knockdown)

    • Orthogonal methods (correlating antibody results with MS or RNA data)

    • Independent antibodies (multiple antibodies targeting different epitopes)

    • Expression of tagged proteins (correlation with tag detection)

    • Immunoprecipitation-mass spectrometry

  • Document and publish complete validation data including negative results

• Standardized methods and controls:

  • Adopt community-established standard operating procedures

  • Include mandatory positive and negative controls in all experiments

  • Implement blinding protocols for analysis where appropriate

• Resource sharing and transparency:

  • Deposit detailed protocols in repositories like protocols.io

  • Share antibody validation data through antibody validation databases

  • Provide complete antibody metadata (catalog numbers, lots, RRID identifiers)

• Collaborative validation initiatives:

  • Participate in multi-laboratory validation studies

  • Contribute to antibody testing consortia

  • Engage with reproducibility initiatives

These approaches directly address the "antibody characterization crisis" that has contributed to reproducibility issues in biomedical research, as highlighted in recent literature .

What factors should researchers consider when selecting between different types of SPAC22E12.01 antibodies for specific applications?

When selecting SPAC22E12.01 antibodies for specific applications, consider:

• Antibody format considerations:

  • Polyclonal antibodies:

    • Advantages: Recognize multiple epitopes, robust to minor protein modifications

    • Best for: Initial characterization, detecting denatured proteins

    • Limitations: Batch-to-batch variability, potential cross-reactivity

  • Monoclonal antibodies:

    • Advantages: Consistent specificity, renewable source, reduced background

    • Best for: Quantitative applications, detecting specific isoforms

    • Limitations: May be sensitive to epitope modifications

  • Recombinant antibodies:

    • Advantages: Defined sequence, renewable, customizable

    • Best for: Reproducible long-term studies, specialized modifications

    • Limitations: Potentially higher cost, fewer validated options

• Application-specific selection criteria:

• Host species implications:

  • Consider compatibility with other antibodies in multiplexed applications

  • Evaluate potential background in your experimental system

  • Assess availability of appropriate secondary detection reagents

• Technical specifications assessment:

  • Review complete validation data for application of interest

  • Evaluate lot-to-lot consistency information

  • Consider detection sensitivity requirements